PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis

PD-1 is a negative costimulator of chronic infectious diseases In this study, we investigated the expression of PD-1 and its ligands in the spleen of dogs with visceral leishmaniasis and lymphoproliferative response to soluble antigen, in lymph node cells in the presence or absence of antibodies blo...

ver descrição completa

Detalhes bibliográficos
Autores: Oliveira Silva, Kathlenn Liezbeth [UNESP], Marin Chiku, Vanessa [UNESP], Luvizotto Venturin, Gabriela [UNESP], Correa Leal, Aline Aparecida [UNESP], de Almeida, Breno Fernando [UNESP], De Rezende Eugenio, Flavia [UNESP], Dos Santos, Paulo Sergio Patto [UNESP], Fabrino Machado, Gisele [UNESP], De Lima, Valeria Marçal Felix [UNESP]
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:Brasil
Recursos:Universidade Estadual Paulista (UNESP)
Repositorio:Repositório Institucional da UNESP
Idioma:inglés
OAI Identifier:oai:repositorio.unesp.br:11449/188514
Acesso em linha:http://dx.doi.org/10.1016/j.cimid.2018.12.002
http://hdl.handle.net/11449/188514
Access Level:acceso abierto
Palavra-chave:Canine
Cytokine
Lymphoproliferation
Nitric oxide
PD-1
Visceral leishmaniasis
Descrição
Resumo:PD-1 is a negative costimulator of chronic infectious diseases In this study, we investigated the expression of PD-1 and its ligands in the spleen of dogs with visceral leishmaniasis and lymphoproliferative response to soluble antigen, in lymph node cells in the presence or absence of antibodies blocking PD-1 and its ligands. Our results showed expression of PD-1 and its ligands is higher after L. infantum infection and in the spleen of infected dogs, PD-1 blockage was able to restore the antigen-dependent lymphoproliferative response and regulated production of the cytokines IL-4 and IL-10 and NO production. We concluded that L. infantum infection modulates PD-1 and its ligands expression in canine VL and that blockage of PD-1 restores the immune response. Thus, blockage of PD-1 is a target for therapeutic drug development.